Why Is Kenvue Stock Rising Today?

Citi noted that Kenvue shares would be trading higher on Tuesday following yesterday's selloff, given the lack of new scientific evidence presented by the Trump administration regarding Tylenol use.

The Kenvue logo is seen displayed on a smartphone screen. U.S. health officials will hold a press conference on autism, which is expected to link Kenvue's Tylenol to the disease. (Illustration by Thomas Fuller/Getty Images)

Ananya Mariam Rajesh·Stocktwits

Published Sep 23, 2025 | 9:13 AM GMT-04

Share this article

Kenvue (KVUE) shares jumped nearly 6% in premarket trading on Tuesday and became the top trending ticker on Stocktwits after Citigroup stated that it sees limited legal risk for the company following President Donald Trump's discouragement of pregnant women from taking Acetaminophen, the active ingredient in Tylenol.

Citi maintained a ‘Neutral rating on the stock with a $20 price target, according to TheFly. Citi expects Kenvue shares to trade higher on Tuesday, following yesterday's selloff, given the lack of new scientific evidence presented by the Trump administration regarding Tylenol use.

Get updates to this developing story directly on Stocktwits.

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Also See: Amazon To Close Its ‘Amazon Fresh UK’ Stores

Subscribe to Trends with No Friends

All Newsletters

High Relative Strength, Low Social Following

Read about our editorial guidelines and ethics policy

Premarket Mid Cap Equities